Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Inhibition of nuclear transcription factor-kB by specific IkB kinase peptide inhibitor.

Authors
Swaroop-N; Chen-F; Wang-L; Dokka-S; Toledo-D; Rojanasakul-Y
Source
Pharm Res 2001 Nov; 18(11):1631-1633
NIOSHTIC No.
20021889
Abstract
Aberrant activation and expression of genes is the major cause of many human diseases. Most genes are quiescent or have minimal activity in affecting physiologic processes. However, in certain pathologic conditions, these genes are abruptly turned on by a preexisting genetic switch, causing them to overexpress. The nuclear transcription factor-kB (NF-kB) is one such important factor that controls the genetic switch for many important genes that encode cytokines, growth factors, adhesion molecules, and some acute phase proteins (1). Abnormal activation of NF-kB is associated with a number of diseases, including immune and inflammatory diseases (see Ref. 2 for review). Because of its pathophysiologic importance, the NF-kB has been identified as a key target for pharmacologic manipulations. The purpose of this study is to investigate a gene inhibition approach using synthetic peptides that inhibit signal-induced degradation of the NF-kB inhibitory subunit IkB by IkB kinases (IKK), thereby preventing NF-kB activation.
Keywords
Genes; Diseases; Physiological-factors; Growth-factors; Proteins
CODEN
PHREEB
Publication Date
20011101
Document Type
Journal Article
Email Address
yrojanasakul@hsc.wvu.edu
Editors
Sadee-W
Fiscal Year
2002
NTIS Accession No.
NTIS Price
Issue of Publication
11
ISSN
0724-8741
NIOSH Division
HELD
Priority Area
Research Tools and Approaches; Other Occupational Concerns
Source Name
Pharmaceutical Research
State
PA; WV
TOP